Abstract
130 serial bone scintigrams were performed to evaluate the course of skeletal metastases under treatment in 36 patients with prostatic cancer. During a successful treatment scintigraphic controls revealed a significant decrease of the metastatic 99mTc-diphosphonate uptake in 14 patients and sometimes even a complete normalization of the skeletal radioactivity distribution, whereas a progression characterized by an increased multifocal radioactivity concentration was registered in 16 patients indicating the failure of the initiated therapy. Based on these results of follow-up studies scintigraphic bone imaging can be recommended for the assessment of the effectiveness of on-going therapy of skeletal metastases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
